Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03689972
Brief Title: A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment

First Submitted : September 27, 2018
First Submitted that Met QC Criteria : September 27, 2018
First Posted : October 1, 2018

Last Update Submitted that Met QC Criteria : November 21, 2019
Last Update Posted : November 22, 2019